Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-03-29
DOI
10.1038/s41598-018-23420-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
- (2017) Farhana Naznin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
- (2017) Yusuke Nakatsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation
- (2017) Sarah J. Mancini et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance
- (2017) Daniel Garcia et al. MOLECULAR CELL
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- Protein kinase C phosphorylates AMP-activated protein kinase 1 Ser487
- (2016) H. R. Heathcote et al. BIOCHEMICAL JOURNAL
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- (2016) Ji Hye Han et al. DIABETOLOGIA
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling
- (2016) C. Rutherford et al. Science Signaling
- Transendothelial glucose transport is not restricted by extracellular hyperglycaemia
- (2016) Sarka Tumova et al. VASCULAR PHARMACOLOGY
- Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling
- (2016) C. Rutherford et al. Science Signaling
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
- (2016) Linda A. Villani et al. Molecular Metabolism
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
- (2015) Ying Han et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
- (2015) Damayanthi Devineni et al. CLINICAL PHARMACOKINETICS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Anti-inflammatory therapies for cardiovascular disease
- (2014) P. M. Ridker et al. EUROPEAN HEART JOURNAL
- The TLR and IL-1 signalling network at a glance
- (2014) P. Cohen JOURNAL OF CELL SCIENCE
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- AMP-dependent Kinase Inhibits Oxidative Stress-induced Caveolin-1 Phosphorylation and Endocytosis by Suppressing the Dissociation between c-Abl and Prdx1 Proteins in Endothelial Cells
- (2013) Kimio Takeuchi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
- (2013) Chen Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway
- (2013) Ming-liang Chen et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
- (2012) Clare Davies et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification
- (2012) Katalin Pinter et al. CELL CYCLE
- Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation
- (2012) Ian P Salt et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- AMP-Activated Protein Kinase Suppresses Endothelial Cell Inflammation Through Phosphorylation of Transcriptional Coactivator p300
- (2011) Yuan Zhang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Nitric Oxide-Induced Activation of the AMP-Activated Protein Kinase α2 Subunit Attenuates IκB Kinase Activity and Inflammatory Responses in Endothelial Cells
- (2011) Elke Bess et al. PLoS One
- Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS
- (2010) Veronika Makó et al. CYTOMETRY PART A
- Inhibition of Tumor Necrosis Factor α–Stimulated Monocyte Adhesion to Human Aortic Endothelial Cells by AMP-Activated Protein Kinase
- (2008) Marie-Ann Ewart et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Rosiglitazone Stimulates Nitric Oxide Synthesis in Human Aortic Endothelial Cells via AMP-activated Protein Kinase
- (2008) James G. Boyle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started